Jci_page_head_homepage_01 Jci_page_head_homepage_02
Lars Johan Nissen, Renhai Cao, Eva-Maria Hedlund, Zongwei Wang, Xing Zhao, Daniel Wetterskog, Keiko Funa, Ebba Bråkenhielm, Yihai Cao
Published in Volume 117, Issue 10
J Clin Invest. 2007; 117(10):2766–2777 doi:10.1172/JCI32479
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
Regulation of mRNA and protein expression of PDGFRs and signaling pathways.

(A) RT-PCR was used to quantitatively measure PDGFR-α and PDGFR-β expression levels in FGF2- or PDGF-BB–treated BCE cells for the indicated time points. GAPDH was used as a standard control. (B) BCE cell lysates treated with different concentrations of FGF2 were immunoblotted with an anti–PDGFR-β antibody and an anti–p-PDGFR-β antibody. An anti–β-actin antibody was used as a standard control for loading levels. (CJ) In situ hybridization. PBS- (C and G), PDGF-BB– (D and H), FGF2- (E and I), or PDGF-BB/FGF2–implanted (F and J) corneas were hybridized in situ with probes for PDGFR-α (CF) and PDGFR-β (GJ) at day 5 after growth factor implantation. Arrows point to positive signals. (K) Analysis of signaling components. FGF2-pretreated BCE cells were treated with PDGF-BB for indicated time points, and cell lysates were immunoblotted with different antibodies. β-Actin was immunoblotted as a control for loading levels. Scale bar: 10 μm.